profenamine hydrochloride has been researched along with Myasthenia Gravis in 2 studies
*Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dohnal, V; Dolezal, M; Holas, O; Hrabinova, M; Komloova, M; Kuca, K; Musilek, K; Nachon, F; Pohanka, M | 1 |
Dohnal, V; Gunn-Moore, F; Holas, O; Horova, A; Komloova, M; Kuca, K; Musilek, K | 1 |
2 other study(ies) available for profenamine hydrochloride and Myasthenia Gravis
Article | Year |
---|---|
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Humans; Isoquinolines; Models, Molecular; Molecular Structure; Myasthenia Gravis; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2011 |
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
Topics: Acetylcholinesterase; Ambenonium Chloride; Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Edrophonium; Humans; Kinetics; Molecular Dynamics Simulation; Myasthenia Gravis; Protein Binding; Quinolinium Compounds; Recombinant Proteins; Structure-Activity Relationship | 2011 |